Morphological Changes of Ciliary Body and Trabecular Meshwork
NCT ID: NCT05352854
Last Updated: 2022-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2022-05-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Health control
emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), best corrected visual acuity ≥1.0
0.5% pilocarpine eye drops
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
High myopia
Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm
0.5% pilocarpine eye drops
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Primary open angle glaucoma
emmetropia/low myopia (equivalent spherical lens \> -3.00d, astigmatism ≤ 1.5d), diagnosed as POAG
0.5% pilocarpine eye drops
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
HM-POAG
Equivalent spherical lens ≤-6.00D or axial length ≥26.5mm,diagnosed as POAG
0.5% pilocarpine eye drops
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.5% pilocarpine eye drops
Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have a good gaze to complete the test required inspection;
Exclusion Criteria
* History of eye surgery, including cataract surgery, anti-glaucoma surgery, corneal surgery, retinal surgery, and eye trauma
* history of systemic diseases that may affect the eyes (such as diabetes, hypertension, etc.)
* intraocular chronic inflammatory diseases (uveitis, etc.), retinal diseases (retinal detachment, diabetic retinopathy, retinitis pigmentosa, etc.)
* Corneal scars and severe cataracts affect OCT imaging
* Eye diseases (angle-closure glaucoma, abnormal anterior segment development, neovascularization, etc.) that can affect trabecular meshwork and Schlemm canal structure.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yune Zhao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yune Zhao
Vice president of Eye Hospital of Wenzhou Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yune Zhao
Role: PRINCIPAL_INVESTIGATOR
Ophthalmology and Optometry Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Yune Zhao, MD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Myopia-OAG SSOCT
Identifier Type: -
Identifier Source: org_study_id